Carregant...
Vulnerable COPD patients with comorbidities: the role of roflumilast
Roflumilast is a selective phosphodiesterase-4 (PDE-4) inhibitor that was approved by the US Food and Drug Administration in February 2011 for the management of chronic obstructive pulmonary disease (COPD). Literature was retrieved through PubMed using the terms “roflumilast” and “COPD”. Reference c...
Guardat en:
| Publicat a: | Ther Clin Risk Manag |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4242693/ https://ncbi.nlm.nih.gov/pubmed/25429225 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S55105 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|